Government-Owned Inventions; Availability for Licensing, 38228-38230 [E8-15178]
Download as PDF
<![CDATA[
38228
Federal Register / Vol. 73, No. 129 / Thursday, July 3, 2008 / Notices
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Proposed Collection: Title: The
Agricultural Health Study: A
Prospective Cohort Study of Cancer and
Other Disease Among Men and Women
in Agriculture (NCI) (OMB#: 0925–
0406). Type of Information Collection
Request: Renewal. Need and Use of
Information Collection: The purpose of
this information collection is to
continue and complete updating the
occupational and environmental
exposure information as well as medical
history information for respondents
percentage of the respondents will also
be asked to participate in a buccal cell
collection which is a sample of loose
cells from the respondent’s mouth. The
findings will provide valuable
information concerning the potential
link between agricultural exposures and
cancer and other chronic diseases
among agricultural Health Study cohort
members, and this information may be
generalized to the entire agricultural
community. Frequency of Response:
Once. Affected Public: Private sector,
farms. Type of Respondents: Licensed
pesticide applicators and their spouses.
The annual reporting burden is as
follows:
enrolled in the Agriculture Health
Study. This represents a request to
continue and complete phase III (2005–
2008) of the study. Due to reduced
annual budgets for research, a delay in
data collection has resulted and there
has not been enough time to complete
the data collection on the number of
respondents that had been originally
requested in the 2005 OMB submission.
The primary objectives of the study are
to determine the health effects resulting
from occupational and environmental
exposures in the agricultural
environment. The data will be collected
by using a computer assisted telephone
interview (CATI) system. A small
ESTIMATES OF ANNUAL BURDEN HOURS
Type of
respondent
Private Applicators ............................
Spouses ............................................
Commercial Applicators ....................
mstockstill on PROD1PC66 with NOTICES
Totals .........................................
Interview
Interview
Interview
Interview
Interview
Interview
16:46 Jul 02, 2008
Frequency of
response
Average time
per response
(Minutes/hour)
Annual burden
hours
Only ..................................
& buccal cells ...................
Only ..................................
& buccal cells ...................
Only ..................................
& buccal cells ...................
2,920
83
2,680
165
930
83
1.00
1.00
1.00
1.00
1.00
1.00
35/60
60/60
35/60
60/60
35/60
60/60
1,703.33
83.00
1,563.33
165.00
542.50
83.00
...........................................................
6,861
........................
........................
4,140.17
The annualized cost to respondents is
estimated at $109,652, which amount to
a total cost of $1,348,000 over three
years. There are no capital costs,
operating costs, and/or maintenance
costs to report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the
Attention: NIH Desk Officer, Office of
VerDate Aug<31>2005
Estimated
number of
respondents
Instrument
Jkt 214001
Management and Budget, at
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Michael
Alavanja, Dr.P.H, Occupational and
Environmental Epidemiology Branch,
Division of Cancer Epidemiology and
Genetics, National Cancer Institute,
NIH, Executive Plaza South, Room 8000,
6120 Executive Blvd., Rockville, MD
20892 or call 301–496–9093 or e-mail
your request, including your address to:
alavanjm@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
Dated: June 25, 2008.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison Office,
National Institutes of Health.
[FR Doc. E8–15072 Filed 7–2–08; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
E:\FR\FM\03JYN1.SGM
03JYN1
Federal Register / Vol. 73, No. 129 / Thursday, July 3, 2008 / Notices
Tendon Stem Cells
Description of Technology: Tendon
injuries due to trauma and overuse are
common clinical problems that result in
significant pain and loss of mobility.
Tendon injuries are slow to heal and the
healed tendon rarely matches the
original in mechanical strength and
structural integrity. Due to a limited
understanding of basic tendon biology,
development of new treatment options
for injured tendons has posed
significant challenges.
This invention relates to a cell based
therapy. Specifically, it relates to the
isolation and enrichment of stem cells
from adult tendons, known as tendon
stem progenitor cells, that can form
tendon structures and are capable of
integrating into bones to form enthesislike structures. Two extra-cellular
matrix proteoglycans, biglycan and
fibromodulin, further assist in the
maintenance and multiplication of these
tendon stem cells.
Applications:
Treatment of damaged tendons that
are slow to repair after injury.
May remedy other pathological
conditions that are caused by ectopic
calcification such as ectopic
calcification that occurs around
artificial heart valves or that develops in
the rare inherited disease,
Fibrodysplasia Ossificans Progressiva
(FOP).
Development Status: Early stage.
Inventors: Marian Young et al.
(NIDCR).
Patent Status: U.S. Provisional
Application No. 60/934,606 filed 14 Jun
2007 (HHS Reference No: E–233–2007/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Fatima Sayyid,
M.H.P.M.; 301–435–4521;
Fatima.Sayyid@nih.hhs.gov.
Collaborative Research Opportunity:
The NIDCR, Molecular Biology of Bones
and Teeth Section is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the use of tendon stem
cells. Please contact Marian Young at
301–496–8860 or
myoung@dir.nidcr.nih.gov.
mstockstill on PROD1PC66 with NOTICES
A2 Adenosine Receptor Agonists
Description of Technology: Four
adenosine receptor subtypes exist,
namely A1, A2A, A2B and A3, each with
different functions, tissue distributions
and ligand coupling abilities. While
activation of A2B AR can induce
angiogenesis, reduce vascular
permeabilization, increase production of
VerDate Aug<31>2005
16:46 Jul 02, 2008
Jkt 214001
the anti-inflammatory cytokine IL–10,
increase chloride secretion in epithelial
cells or increase release of inflammatory
mediators from human and canine mast
cells, there still remains a need for A2B
receptor agonists for clinical use.
Recognizing that an unmet medical
need exists, the inventors synthesized
an assortment of adenosine derivatives
with the goal of preparing highly potent
and selective A2B receptor agonists.
They identified a compound as a full
agonist at the A2A and A2B adenosine
receptors, capable of reducing infarct
size in rabbit hearts induced by 30
minutes of ischemia. As activation of
A2A and A2B receptors induces a
cardioprotective effect and this
compound activates both A2A and A2B
receptors, this compound may be
beneficial for protecting against
myocardial ischemia/reperfusion injury.
Available for licensing and
commercial development are
compositions and methods of use of A2
adenosine receptor (AR) agonists for
treating conditions modulated by A2A
and A2B ARs including myocardial
ischemia, reperfusion injury, cystic
fibrosis, erectile dysfunction,
inflammation, restenosis and septic
shock.
Applications:
Potential treatment for heart attacks.
Potential treatment of septic shock,
cystic fibrosis and erectile dysfunction.
Potential treatment for medical
conditions that would benefit from
changes in vascular tone.
Market: Heart disease is the number
one cause of death in the United States,
and the most frequent cause of hospital
admission for patients over 65 years of
age.
Development Status: Early-stage of
development.
Inventors: Kenneth A. Jacobson et al.
(NIDDK).
Patent Status:
U.S. Provisional Application No. 60/
947,066 filed 29 Jun 2007 (HHS
Reference No. E–218–2007/0–US–01).
U.S. Provisional Application No. 60/
950,250 filed 17 Jul 2007 (HHS
Reference No. E–218–2007/1–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Charlene A.
Sydnor, PhD.; 301–435–4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity:
The NIDDK Laboratory of Bioorganic
Chemistry is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize A2A and A2B adenosine
receptor agonists. Please contact
Rochelle S. Blaustein at 301–451–3636
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
38229
or Rochelle.Blaustein@nih.gov for more
information.
Therapeutic Application of Fatty Acid
Amide Hydrolase Inhibitors
Description of Technology: The
enzyme fatty acid amide hydrolase
(FAAH) is responsible for the
degradation of the lipid anandamide.
This is a cannabinoid naturally secreted
from both the brain and body.
Cannabinoid receptors mediate blood
pressure, pain sensation, hunger and
anxiety among other actions. Drugs
inhibiting FAAH increase cannabinoid
receptor activity in a manner distinct
from cannabinoid agonists to treat
hypertension, relieve pain or have other
therapeutic effect with lessened side
effects.
Applications:
Treat hypertension and accompanying
cardiac hypertrophy.
Treatment of anxiety.
Treatment of glaucoma.
As a pain reliever or sleep aid.
Market:
It is estimated that nearly a third of
U.S. adults have high blood pressure.
Despite the lack of symptoms, treatment
is imperative. People with untreated
high blood pressure have an increased
chance of developing stroke, heart
attack, heart failure or kidney failure.
The forecast of the world
hypertension market is that it will grow
to nearly $30 billion per year by 2010.
Development Status: Pre-clinical data
available.
Inventors: George Kunos (NIAAA) et
al.
´
Publication: Batkai S, Pacher P, OseiHyiaman D, Radaeva S, Liu J, Harvey´
White J, Offertaler L, Mackie K, Rudd
MA, Bukoski RD, Kunos G.
Endocannabinoids acting at
cannabinoid-1 receptors regulate
cardiovascular function in
hypertension. Circulation. 2004 Oct
5;110(14):1996–2002.
Patent Status: U.S. Provisional
Application No. 60/998,661 filed 12 Dec
2007 (HHS Reference No. E–211–2006/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Norbert Pontzer,
J.D., PhD.; 301–435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The NIAAA Laboratory of Physiologic
Studies is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize fatty acid amide
hydrolase inhibitors. Please contact
Peter B. Silverman
(psilverm@mail.nih.gov) for more
information.
E:\FR\FM\03JYN1.SGM
03JYN1
38230
Federal Register / Vol. 73, No. 129 / Thursday, July 3, 2008 / Notices
Dated: June 27, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–15178 Filed 7–2–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
mstockstill on PROD1PC66 with NOTICES
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
A Prophylactic and Therapeutic for
Preventing and Treating Tularemia by
Rapid Activation of Host Cells and
Antigen Recognition
Description of Technology: The
invention is a composition and method
for prophylactic and therapeutic
treatment of tularemia caused by
Francisella tularensis comprised of
Cationic Liposome DNA Complexes
(CLDC) complexed with noncoding
DNA and membrane antigens isolated
from F. tularensis strain LVS (MPF). F.
tularensis is category A pathogen (as
designated by the NIH) that was
previously weaponized by both the
former Soviet Union and the United
States of America and is currently a
potential bioweapon and bioterrorism
threat. Furthermore, tularemia is
endemic to the U.S. (majority of the
cases occurring in the Midwest) and
Europe. The prophylactic and
therapeutic activities of this invention
VerDate Aug<31>2005
16:46 Jul 02, 2008
Jkt 214001
rely in part on rapid activation of host
cells and recognition of bacterial
antigens. In vivo studies in mice show
that CLDC + MPF elicit protective
immunity against pneumonic tularemia
when administered shortly (days) prior
to exposure to aerosols of virulent F.
tularensis. The method can be
applicable for eliciting immune
response in other infectious diseases.
Applications:
Prophylactic and therapeutic for
Tularemia.
Biodefense agent.
Method is applicable to other
infectious diseases, particularly for
pathogens that are enveloped or
encapsulated (i.e. Pseudomonas
aeruginosa, Neisseria meningiditis,
Yersinia pestis and Influenza).
Advantages:
Rapid induction of protective
immunity against F. tularensis.
Avoids antibiotic resistance
associated with current therapies.
Development Status: In vitro and in
vivo data are available.
Market:
Prophylactic and treatment for
tularemia and other infectious diseases.
Biodefense.
Inventors: Catherine M. Bosio
(NIAID).
Publication: PowerPoint slide
presentation of invention can be
provided upon request.
Patent Status: U.S. Provisional
Application No. 61/030,984 filed 24 Feb
2008 (HHS Reference No. E–095–2008/
0–US–01).
Licensing Status: This invention is
available for exclusive or non-exclusive
licensing.
Licensing Contact: Sally Hu, PhD.;
301–435–5606, HuS@mail.nih.gov.
A New Method for Screening of Antitumor Agents
Description of Technology:
Astrocytomas and glioblastoma
multiforme are the most common forms
of malignant brain cancer, and are often
unresponsive to surgical removal and
pharmacological therapy. The 5 year
survival rate of glioblastoma is 5%,
thus, making it necessary for the
identification of more effective antitumor agents. Individuals with the
familial cancer syndrome
neurofibromatosis type 1 are
predisposed to developing multiple
tumors including astrocytoma and
glioblastoma.
Scientists at NCI have discovered a
new technology that will help screen
multiple anti-tumor and antineurofibromatosis agents in a high
throughput assay by using an
astrocytoma cell line (KR158) that
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
expresses the luciferase gene under the
influence of dual promoters, E2F and
CMV.
This new technology distinguishes
between cytostatic and cytotoxic
compounds, thereby significantly
reducing the time and cost required to
screen anti-tumor agents.
Advantages:
Quantifiable.
Can be used in high throughput
assays.
Distinguishes between cytostatic and
cytotoxic activity of compounds.
Applications:
Cancer therapeutics.
Gene therapy.
Screening of anti-tumor agents.
Screening of anti-neurofibromatosis
agents.
Pharmacology of drugs.
Market: Neurofibromatoses is
inherited by many affected individuals
and occurs in 1 in 3500 individuals. In
addition, between 30 and 50 percent of
new cases arise spontaneously through
mutation in an individual’s genes which
can then be passed on to succeeding
generations, leading to increased tumor
risk. Astrocytomas and glioblastoma
multiforme are the most common
malignant brain tumor in adults with
very poor prognosis.
Development Status: Late-stage.
Inventors: Jessica J. Hawes and
Karlyne M. Reilly (NCI).
Patent Status: HHS Reference No. E–
038–2008/0—Research Tool. Patent
protection is not being sought for this
technology.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: John Stansberry,
Ph.D.; 301–435–5236;
stansbej@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute Mouse
Cancer Genetics Program is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize anti-astrocytoma or antineurofibromatosis therapy. Please
contact John D. Hewes, PhD., at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
A Novel Therapeutic Strategy for the
Treatment of Hyperpigmentation and
Melanoma
Description of Technology: The
present invention describes that the
transcription factor SOX9 is expressed
by normal human melanocytes in vitro
and in the skin in vivo, and that overexpression of SOX9 decreases the
proliferation of mouse and human
melanoma cell lines via several
pathways. Furthermore, SOX9 (or its
E:\FR\FM\03JYN1.SGM
03JYN1
]]>Agencies
[Federal Register Volume 73, Number 129 (Thursday, July 3, 2008)]
[Notices]
[Pages 38228-38230]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-15178]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
[[Page 38229]]
Tendon Stem Cells
Description of Technology: Tendon injuries due to trauma and
overuse are common clinical problems that result in significant pain
and loss of mobility. Tendon injuries are slow to heal and the healed
tendon rarely matches the original in mechanical strength and
structural integrity. Due to a limited understanding of basic tendon
biology, development of new treatment options for injured tendons has
posed significant challenges.
This invention relates to a cell based therapy. Specifically, it
relates to the isolation and enrichment of stem cells from adult
tendons, known as tendon stem progenitor cells, that can form tendon
structures and are capable of integrating into bones to form enthesis-
like structures. Two extra-cellular matrix proteoglycans, biglycan and
fibromodulin, further assist in the maintenance and multiplication of
these tendon stem cells.
Applications:
Treatment of damaged tendons that are slow to repair after injury.
May remedy other pathological conditions that are caused by ectopic
calcification such as ectopic calcification that occurs around
artificial heart valves or that develops in the rare inherited disease,
Fibrodysplasia Ossificans Progressiva (FOP).
Development Status: Early stage.
Inventors: Marian Young et al. (NIDCR).
Patent Status: U.S. Provisional Application No. 60/934,606 filed 14
Jun 2007 (HHS Reference No: E-233-2007/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521;
Fatima.Sayyid@nih.hhs.gov.
Collaborative Research Opportunity: The NIDCR, Molecular Biology of
Bones and Teeth Section is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize the use of tendon stem cells. Please contact
Marian Young at 301-496-8860 or myoung@dir.nidcr.nih.gov.
A2 Adenosine Receptor Agonists
Description of Technology: Four adenosine receptor subtypes exist,
namely A1, A2A, A2B and A3, each with different functions, tissue
distributions and ligand coupling abilities. While activation of A2B AR
can induce angiogenesis, reduce vascular permeabilization, increase
production of the anti-inflammatory cytokine IL-10, increase chloride
secretion in epithelial cells or increase release of inflammatory
mediators from human and canine mast cells, there still remains a need
for A2B receptor agonists for clinical use.
Recognizing that an unmet medical need exists, the inventors
synthesized an assortment of adenosine derivatives with the goal of
preparing highly potent and selective A2B receptor agonists. They
identified a compound as a full agonist at the A2A and A2B adenosine
receptors, capable of reducing infarct size in rabbit hearts induced by
30 minutes of ischemia. As activation of A2A and A2B receptors induces
a cardioprotective effect and this compound activates both A2A and A2B
receptors, this compound may be beneficial for protecting against
myocardial ischemia/reperfusion injury.
Available for licensing and commercial development are compositions
and methods of use of A2 adenosine receptor (AR) agonists for treating
conditions modulated by A2A and A2B ARs including myocardial ischemia,
reperfusion injury, cystic fibrosis, erectile dysfunction,
inflammation, restenosis and septic shock.
Applications:
Potential treatment for heart attacks.
Potential treatment of septic shock, cystic fibrosis and erectile
dysfunction.
Potential treatment for medical conditions that would benefit from
changes in vascular tone.
Market: Heart disease is the number one cause of death in the
United States, and the most frequent cause of hospital admission for
patients over 65 years of age.
Development Status: Early-stage of development.
Inventors: Kenneth A. Jacobson et al. (NIDDK).
Patent Status:
U.S. Provisional Application No. 60/947,066 filed 29 Jun 2007 (HHS
Reference No. E-218-2007/0-US-01).
U.S. Provisional Application No. 60/950,250 filed 17 Jul 2007 (HHS
Reference No. E-218-2007/1-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Charlene A. Sydnor, PhD.; 301-435-4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity: The NIDDK Laboratory of
Bioorganic Chemistry is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize A2A and A2B adenosine
receptor agonists. Please contact Rochelle S. Blaustein at 301-451-3636
or Rochelle.Blaustein@nih.gov for more information.
Therapeutic Application of Fatty Acid Amide Hydrolase Inhibitors
Description of Technology: The enzyme fatty acid amide hydrolase
(FAAH) is responsible for the degradation of the lipid anandamide. This
is a cannabinoid naturally secreted from both the brain and body.
Cannabinoid receptors mediate blood pressure, pain sensation, hunger
and anxiety among other actions. Drugs inhibiting FAAH increase
cannabinoid receptor activity in a manner distinct from cannabinoid
agonists to treat hypertension, relieve pain or have other therapeutic
effect with lessened side effects.
Applications:
Treat hypertension and accompanying cardiac hypertrophy.
Treatment of anxiety.
Treatment of glaucoma.
As a pain reliever or sleep aid.
Market:
It is estimated that nearly a third of U.S. adults have high blood
pressure. Despite the lack of symptoms, treatment is imperative. People
with untreated high blood pressure have an increased chance of
developing stroke, heart attack, heart failure or kidney failure.
The forecast of the world hypertension market is that it will grow
to nearly $30 billion per year by 2010.
Development Status: Pre-clinical data available.
Inventors: George Kunos (NIAAA) et al.
Publication: B[aacute]tkai S, Pacher P, Osei-Hyiaman D, Radaeva S,
Liu J, Harvey-White J, Offert[aacute]ler L, Mackie K, Rudd MA, Bukoski
RD, Kunos G. Endocannabinoids acting at cannabinoid-1 receptors
regulate cardiovascular function in hypertension. Circulation. 2004 Oct
5;110(14):1996-2002.
Patent Status: U.S. Provisional Application No. 60/998,661 filed 12
Dec 2007 (HHS Reference No. E-211-2006/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Norbert Pontzer, J.D., PhD.; 301-435-5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity: The NIAAA Laboratory of
Physiologic Studies is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize fatty acid amide hydrolase inhibitors.
Please contact Peter B. Silverman (psilverm@mail.nih.gov) for more
information.
[[Page 38230]]
Dated: June 27, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-15178 Filed 7-2-08; 8:45 am]
BILLING CODE 4140-01-P
